Table 2. Selected treatment regimens.
| Treatment Regimen | GT1b n = 1,654, n (%) |
GT1a n = 455, n (%) |
GT4 n = 291, n (%) |
Other, n (%) n = 11 |
Total, n (%) N = 2,408 |
||||
|---|---|---|---|---|---|---|---|---|---|
| Without Cirrhosis n = 1,037 |
With Compensated Cirrhosis* n = 614 |
Without Cirrhosis n = 278 |
With Compensated Cirrhosis n = 177 |
Without Cirrhosis n = 217 |
With Compensated Cirrhosis n = 74 |
||||
| Regimen received |
OBV/PTV/r + RBV 12 weeks | 1 (0.2) | 1 (0.6) | 184 (84.8) | 10 (13.5) | 196 (8.1) | |||
| OBV/PTV/r 12 weeks | 18 (1.7) | 2 (0.3) | 3 (1.4) | 1 (1.4) | 24 (1.0) | ||||
| OBV/PTV/r + RBV 24 weeks | 1 (0.2) | 1 (0.6) | 11 (5.1) | 59 (79.7) | 1 (9.1) | 73 (3.0) | |||
| OBV/PTV/r + DSV + RBV 12 weeks | 66 (6.4) | 393 (64.0) | 244 (87.8) | 23 (13.0) | 13 (6.0) | 7 (63.6) | 746 (31.0) | ||
| OBV/PTV/r + DSV 12 weeks | 944 (91.0) | 205 (33.4) | 15 (5.4) | 1 (0.6) | 4 (1.8) | 1,169 (48.5) | |||
| OBV/PTV/r + DSV + RBV 24 weeks | 3 (0.3) | 9 (1.5) | 13 (4.7) | 150 (84.7) | 2 (0.9) | 3 (4.1) | 3 (27.3) | 183 (7.6) | |
| OBV/PTV/r + DSV 24 weeks | 6 (0.6) | 3 (0.5) | 6 (2.2) | 1 (0.6) | 1 (1.4) | 17 (0.7) | |||
| On-label treatment** | Yes | 944 (91.0) | 598 (97.4) | 244 (87.8) | 150 (84.7) | 184 (84.8) | 59 (79.7) | 11 (100) | 2,190 (90.9) |
| No | 93 (9.0) | 16 (2.6) | 34 (12.2) | 27 (15.3) | 33 (15.2) | 15 (20.3) | 218 (9.1) | ||
Abbreviations: DSV, dasabuvir; GT, genotype; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin.
* Note: Although OBV/PTV/r ± DSV has no indication in patients with decompensated cirrhosis, some patients with decompensated cirrhosis have been included according to the Child-Pugh Score. Use of OBV/PTV/r + DSV regarding treatment duration and concomitant use of RBV based on approved label is set in bold; summary per groups is shown here for on- and off-label treatment.
** The term on-label refers to the treatment that has been administer according to the EU Summary of Product Characteristics (SmPC).